Jyothy Labs (532926) Q2 24/25 earnings summary

Executive summary

• Q2 FY25 consolidated sales reached INR 734 crores (₹73,376 lacs), with 0.2% value and 3% volume growth year-over-year, and a 5.5% 2-year CAGR by value.

• Gross margin improved to 50.2% from 49.2% last year; operating EBITDA margin rose to 18.9%, and PAT for Q2 FY25 was INR 105 crores (₹10,502 lacs).

• Rural demand improved, e-commerce and quick commerce channels saw robust growth, and brand investments included new campaigns and celebrity endorsements.

• Board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2024, with no material misstatements identified by auditors.

• Cash balance stood at INR 659 crores (Rs 658.6 crore) as of September 30, 2024.

Financial highlights

• H1 FY25 revenue was INR 1,476 crores (₹1,47,557 lacs), up 4% in value and 7% in volume, with a gross margin of 50.7%.

• Operating EBITDA for H1 FY25 was Rs 271.9 crore (18.4% margin), and PAT reached Rs 206.7 crore.

• Advertising and promotional spend increased to 8.3% of sales, up from 6.4% last year.

• Dividend payout of INR 128 crores (₹12,852 lacs) during H1 FY25.

• Net cash from operating activities for H1 FY25 was ₹18,879 lacs.

Outlook and guidance

• Margin guidance for FY25 remains at 16%-17% EBITDA, despite achieving 18.5% in H1, due to potential raw material price volatility and planned brand investments.

• Q3 is expected to see mid- to high-single-digit volume growth, with price hikes in soaps and other categories likely in Q4.

• Focus on volume growth through rural distribution expansion, direct retail presence, and new product launches.

• Long-term optimism driven by premiumization, operational efficiencies, and strategic priorities including cost optimization and new category adoption.

• No explicit forward-looking statements or guidance provided in the statutory review.